Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2025 = ×
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates a declining trend in overall profitability as measured by Return on Equity (ROE). This decline is influenced by both asset efficiency and the degree of financial leverage employed. A two-component disaggregation reveals the interplay between Return on Assets (ROA) and Financial Leverage in driving ROE performance.

Return on Equity (ROE)
ROE experienced a consistent decrease from 18.94% in 2021 to 12.55% in 2025. The most significant decline occurred between 2021 and 2023, falling from 18.94% to 12.83%. The rate of decline moderated in subsequent years, with relatively small changes observed between 2023 and 2025.
Return on Assets (ROA)
ROA exhibited a downward trajectory throughout the period, decreasing from 8.12% in 2021 to 6.08% in 2025. Similar to ROE, the largest decrease in ROA occurred between 2021 and 2023, dropping to 6.07%. A slight recovery was noted in 2024 (6.51%), but this was not sustained into 2025. This suggests a diminishing ability to generate earnings from its asset base.
Financial Leverage
Financial Leverage generally decreased from 2.33 in 2021 to a low of 1.96 in 2024. However, it increased slightly in 2025 to 2.07. While leverage decreased overall, its impact on ROE is complex, as it is being applied to a declining asset base profitability (ROA). The reduction in leverage partially offset the negative impact of the declining ROA on ROE, but was insufficient to prevent the overall ROE decline.

The observed decline in ROE is primarily driven by the decreasing ROA. While financial leverage decreased, its effect was not enough to counteract the diminishing profitability of assets. The stabilization of ROE between 2023 and 2025 suggests that the rate of deterioration in asset efficiency may be slowing, but further investigation is needed to determine if this represents a sustained trend.


Three-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates a fluctuating performance in key profitability and efficiency metrics. Return on Equity (ROE) experienced a consistent decline from 2021 to 2025, while the contributing factors – Net Profit Margin, Asset Turnover, and Financial Leverage – exhibited varied trends.

Net Profit Margin
The Net Profit Margin began at 19.70% in 2021, decreased to 15.47% in 2022, and continued a downward trajectory to 13.99% in 2023. A slight recovery was observed in 2024, reaching 14.77%, followed by a further increase to 15.05% in 2025. This indicates improving profitability in the latter years of the period, though not returning to the levels seen in 2021.
Asset Turnover
Asset Turnover showed an initial increase from 0.41 in 2021 to 0.46 in 2022. Subsequently, it decreased to 0.43 in 2023 and 0.44 in 2024 before declining to 0.40 in 2025. This suggests a diminishing efficiency in utilizing assets to generate revenue towards the end of the period.
Financial Leverage
Financial Leverage decreased steadily from 2.33 in 2021 to 1.96 in 2024. A slight increase was noted in 2025, with the ratio rising to 2.07. This indicates a reduction in the reliance on debt financing, followed by a modest re-introduction of leverage in the final year.

The decline in ROE appears to be primarily driven by the initial decrease in Net Profit Margin and the subsequent decrease in Asset Turnover. While Financial Leverage decreased overall, its impact on ROE was less pronounced than the changes in profitability and asset utilization. The slight improvements in Net Profit Margin in 2024 and 2025 were insufficient to offset the negative trends in Asset Turnover and the initial decline in profitability, resulting in the continued downward trend in ROE.

The interplay between these three components suggests a shifting operational dynamic. The company initially benefited from higher profitability, but this advantage eroded over time. While asset utilization initially improved, it ultimately declined, contributing to the overall decrease in ROE. The reduction in financial leverage may indicate a more conservative financial strategy, but it did not fully mitigate the impact of the other factors.


Five-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × × × ×
Dec 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The five-component DuPont analysis reveals shifts in the drivers of Return on Equity (ROE) over the five-year period. Overall, ROE experienced a consistent decline from 18.94% in 2021 to 12.55% in 2025. This decrease was not attributable to a single factor, but rather a combination of changes across several key ratios.

Tax Burden
The tax burden generally increased from 0.87 in 2021 to 0.95 in 2023, before decreasing slightly to 0.92 in 2025. This indicates a modestly increasing effective tax rate, contributing incrementally to the reduction in ROE, particularly in 2023. The impact appears limited, however, as the changes are relatively small.
Interest Burden
The interest burden demonstrated a decreasing trend from 0.94 in 2021 to 0.82 in 2023, suggesting improved efficiency in managing interest expenses. However, this trend reversed slightly in 2024 and 2025, increasing to 0.84 and 0.84 respectively. The initial decrease positively impacted ROE, while the later stabilization represents a neutral effect.
EBIT Margin
The EBIT margin experienced a significant decline from 23.90% in 2021 to 18.66% in 2022, and continued to 17.86% in 2023. While a modest recovery occurred in 2024 and 2025, reaching 19.55% and 19.46% respectively, the margin remained below the 2021 level. This reduction in profitability represents the most substantial negative driver of the overall ROE decline.
Asset Turnover
Asset turnover increased from 0.41 in 2021 to 0.46 in 2022, indicating improved efficiency in utilizing assets to generate sales. However, it subsequently decreased to 0.43 in 2023 and 0.44 in 2024, before falling to 0.40 in 2025. This fluctuating trend suggests inconsistent performance in asset utilization, with the 2025 level being the lowest observed during the period, contributing to the ROE decline.
Financial Leverage
Financial leverage decreased consistently from 2.33 in 2021 to 1.96 in 2024, indicating a reduction in the use of debt financing. A slight increase to 2.07 was observed in 2025. The declining leverage initially dampened the positive impact on ROE, as increased leverage can amplify returns, but the effect was limited. The 2025 increase suggests a minor shift back towards utilizing financial leverage.

In summary, the decline in ROE appears primarily driven by the reduction in EBIT margin and, to a lesser extent, the fluctuating asset turnover. While changes in tax burden, interest burden, and financial leverage also played a role, their impact was comparatively smaller. The interplay of these five components highlights a shift in the company’s profitability and operational efficiency over the analyzed period.


Two-Component Disaggregation of ROA

Thermo Fisher Scientific Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2025 = ×
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates fluctuations in profitability and efficiency. Return on Assets (ROA) experienced a decline from 2021 to 2023, followed by a partial recovery in 2024, and a subsequent slight decrease in 2025. This ROA movement is attributable to offsetting trends in Net Profit Margin and Asset Turnover.

Net Profit Margin
The Net Profit Margin exhibited a notable decrease from 19.70% in 2021 to 13.99% in 2023. A recovery began in 2024, reaching 14.77%, and continued modestly into 2025, with a margin of 15.05%. This suggests improving profitability in the latter years of the period, though not returning to the levels seen in 2021.
Asset Turnover
Asset Turnover showed an initial increase from 0.41 in 2021 to 0.46 in 2022. Subsequently, it decreased to 0.43 in 2023 and 0.44 in 2024 before declining to 0.40 in 2025. This indicates a diminishing ability to generate sales from the company’s asset base towards the end of the period.

The decline in ROA from 2021 to 2023 was primarily driven by the substantial decrease in Net Profit Margin, despite an initial increase in Asset Turnover. The partial ROA recovery in 2024 coincided with further improvement in Net Profit Margin, partially offset by a slight decrease in Asset Turnover. The final year, 2025, shows a slight decline in ROA due to a decrease in Asset Turnover, even with a continued, albeit small, improvement in Net Profit Margin. The interplay between these two components suggests that profitability is becoming a more significant driver of ROA than asset utilization.

ROA Decomposition
The observed trends indicate a shift in the drivers of ROA. While asset efficiency initially contributed positively, its subsequent decline has placed greater emphasis on maintaining and improving profitability to sustain overall returns. The company’s ability to further improve its Net Profit Margin will be crucial in offsetting the decreasing Asset Turnover and supporting ROA in future periods.

Four-Component Disaggregation of ROA

Thermo Fisher Scientific Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2025 = × × ×
Dec 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The four-component disaggregation of Return on Assets (ROA) reveals several noteworthy trends between 2021 and 2025. Overall, ROA experienced a decline from 8.12% in 2021 to 6.08% in 2025, although with some fluctuation in intervening years. This fluctuation is attributable to offsetting movements in the components of the DuPont analysis.

EBIT Margin
The EBIT Margin demonstrated an initial decrease from 23.90% in 2021 to 18.66% in 2022, followed by a period of relative stability and a slight increase to 19.55% in 2024. It concluded at 19.46% in 2025. While the margin experienced volatility, it remained relatively consistent between 2023 and 2025, suggesting a stabilization of core profitability.
Asset Turnover
Asset Turnover exhibited an increase from 0.41 in 2021 to 0.46 in 2022, indicating improved efficiency in utilizing assets to generate sales. However, this improvement was not sustained, with the ratio decreasing to 0.43 in 2023 and 0.44 in 2024 before falling to 0.40 in 2025. This suggests a diminishing ability to generate revenue from its asset base towards the end of the period.
Interest Burden
The Interest Burden generally decreased from 0.94 in 2021 to 0.82 in 2023, indicating a reduced impact of interest expenses on earnings. A slight increase was observed in 2024 (0.83) and 2025 (0.84), but the burden remained below the level recorded in 2021 and 2022. This suggests improved financial leverage management for the majority of the period.
Tax Burden
The Tax Burden consistently increased from 0.87 in 2021 to 0.95 in 2023, reflecting a higher proportion of pre-tax profits retained after tax payments. It then decreased slightly to 0.91 in 2024 and remained at 0.92 in 2025. This indicates a relatively stable tax position in the latter years of the period.

The decline in ROA from 2021 to 2025 appears to be primarily driven by the decrease in Asset Turnover, despite a relatively stable EBIT Margin and a decreasing Interest Burden. The increasing Tax Burden also contributed to the overall decline, though to a lesser extent. The interplay between these factors suggests a shift in the company’s operational efficiency and profitability dynamics over the observed timeframe.


Disaggregation of Net Profit Margin

Thermo Fisher Scientific Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates fluctuations in profitability metrics, influenced by changes in tax and interest expenses. A general observation is a decline in net profit margin from 2021 to 2023, followed by a modest recovery in the subsequent two years. This analysis disaggregates the net profit margin to understand the underlying drivers of these changes.

Net Profit Margin
Net profit margin decreased from 19.70% in 2021 to 13.99% in 2023, representing a significant contraction. A subsequent increase is noted, reaching 15.05% in 2025, but remains below the 2021 level. This suggests a recovery in profitability, though not a full restoration to prior performance.
EBIT Margin
The EBIT margin experienced a decline from 23.90% in 2021 to 17.86% in 2023, mirroring the trend in net profit margin. A recovery is then observed, with the EBIT margin reaching 19.55% in 2024 and 19.46% in 2025. The relatively stable EBIT margin in the latter years suggests that operational profitability is stabilizing, and changes in net profit margin are primarily driven by factors beyond core operations.
Tax Burden
The tax burden increased steadily from 0.87 in 2021 to a peak of 0.95 in 2023. This indicates a higher proportion of pre-tax income being allocated to taxes. The tax burden then decreased slightly to 0.91 in 2024 and remained relatively stable at 0.92 in 2025. The increase in tax burden from 2021 to 2023 likely contributed to the decline in net profit margin during that period.
Interest Burden
The interest burden decreased from 0.94 in 2021 to 0.82 in 2023, suggesting a reduction in the proportion of pre-tax income consumed by interest expenses. However, it then increased slightly to 0.83 in 2024 and 0.84 in 2025. The decrease in interest burden from 2021 to 2023 partially offset the negative impact of the increasing tax burden on net profit margin, but the subsequent increase in interest burden may have limited the recovery in net profit margin from 2023 to 2025.

In summary, the decline in net profit margin from 2021 to 2023 appears to be primarily driven by an increase in the tax burden, with a mitigating effect from a decrease in the interest burden. The subsequent recovery in net profit margin is linked to stabilization of the EBIT margin and a slight decrease in the tax burden, although the increasing interest burden partially counteracts this positive trend.